Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedA minor site version update from v3.4.1 to v3.4.2 with no visible changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1; no study-related content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page shows a site revision update from v3.3.3 to v3.3.4 in the footer, with no visible changes to study details, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a Locations section showing the study site in Columbus, Ohio. Removed the previous Ohio Locations entry; page revision updated to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study details appear to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedThe bottom notice about government funding and operating status was removed, with no changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.